Clinical Cancer Research The Science of Cancer Health Disparities Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Slaton, J. W.
Right arrow Articles by Fidler, I. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slaton, J. W.
Right arrow Articles by Fidler, I. J.
Clinical Cancer Research Vol. 5, 2726-2734, October 1999
© 1999 American Association for Cancer Research

Advances in Brief

Interferon-{alpha}-mediated Down-Regulation of Angiogenesis-related Genes and Therapy of Bladder Cancer Are Dependent on Optimization of Biological Dose and Schedule1

Joel W. Slaton2, Paul Perrotte2, Keiji Inoue, Colin P. N. Dinney and Isaiah J. Fidler3

Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

The purpose of this study was to identify and optimize the antiangiogenic activity of IFN-{alpha} against human bladder cancer cells growing in the bladder of nude mice. 253J B-V IFNR cells (resistant to antiproliferative effects of IFN-{alpha} or IFN-{beta}) were implanted into the bladder wall of nude mice. Three days later, the mice were treated with s.c. injections of IFN-{alpha} (70,000 units/week) at different dosing schedules (1, 2, 3, or 7 times/week). Daily therapy with IFN-{alpha} produced the most significant inhibition of tumor growth, tumor vascularization, and down-regulation of basic fibroblast growth factor and matrix metalloprotease-9 mRNA and protein expression. Changing dose and schedule of IFN-{alpha} administration had minimal effects on the expression of vascular endothelial growth factor or interleukin 8. The daily s.c. administrations of 5,000 or 10,000 units IFN-{alpha}-2a produced maximal inhibition of bFGF and MMP-9 expression (mRNA and protein), maximal reduction in tumor vessel density, and maximal reduction in serum levels of bFGF. Daily administration of higher doses of IFN-{alpha} failed to produce significant antiangiogenic effects. These data suggest that the antiangiogenic activity of IFN-{alpha} is dependent on frequent administration of optimal biological dose and not maximal tolerated dose.




This article has been cited by other articles:


Home page
 Ann OncolHome page
B. Melichar, P. Koralewski, A. Ravaud, A. Pluzanska, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, R. Delva, E. Sevin, et al.
First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma
Ann. Onc., August 1, 2008; 19(8): 1470 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Airoldi, C. Cocco, N. Giuliani, M. Ferrarini, S. Colla, E. Ognio, G. Taverniti, E. Di Carlo, G. Cutrona, V. Perfetti, et al.
Constitutive expression of IL-12R{beta}2 on human multiple myeloma cells delineates a novel therapeutic target
Blood, August 1, 2008; 112(3): 750 - 759.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
C. R. Rossi, F. Russano, S. Mocellin, V. Chiarion-Sileni, M. Foletto, P. Pilati, L. G. Campana, A. Zanon, G. F. Picchi, M. Lise, et al.
TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial
Ann. Surg. Oncol., April 1, 2008; 15(4): 1218 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Donate, G. C. Parry, Y. Shaked, H. Hensley, X. Guan, I. Beck, Z. Tel-Tsur, M. L. Plunkett, M. Manuia, D. E. Shaw, et al.
Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth
Clin. Cancer Res., April 1, 2008; 14(7): 2137 - 2144.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T.-Y. Lee, R. M. Tjin Tham Sjin, S. Movahedi, B. Ahmed, E. A. Pravda, K.-M. Lo, S. D. Gillies, J. Folkman, and K. Javaherian
Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy
Clin. Cancer Res., March 1, 2008; 14(5): 1487 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Folkman
Endostatin finds a new partner: nucleolin
Blood, October 15, 2007; 110(8): 2786 - 2787.
[Full Text] [PDF]

Home page
 JCOHome page
C. W. Ryan, B. H. Goldman, P. N. Lara Jr, P. C. Mack, T. M. Beer, C. M. Tangen, D. Lemmon, C.-X. Pan, H. A. Drabkin, and E. D. Crawford
Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group
J. Clin. Oncol., August 1, 2007; 25(22): 3296 - 3301.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
P. V. Dickson, J. B. Hamner, C. J. Streck, C. Y.C. Ng, M. B. McCarville, C. Calabrese, R. J. Gilbertson, C. F. Stewart, C. M. Wilson, M. W. Gaber, et al.
Continuous Delivery of IFN-{beta} Promotes Sustained Maturation of Intratumoral Vasculature
Mol. Cancer Res., June 1, 2007; 5(6): 531 - 542.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Kalie, D. A. Jaitin, R. Abramovich, and G. Schreiber
An Interferon {alpha}2 Mutant Optimized by Phage Display for IFNAR1 Binding Confers Specifically Enhanced Antitumor Activities
J. Biol. Chem., April 13, 2007; 282(15): 11602 - 11611.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. I. Rini
Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions
Clin. Cancer Res., February 15, 2007; 13(4): 1098 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Papageorgiou, A. Kamat, W. F. Benedict, C. Dinney, and D. J. McConkey
Combination therapy with IFN-{alpha} plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells
Mol. Cancer Ther., December 1, 2006; 5(12): 3032 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Celik, O. Surucu, C. Dietz, J. V. Heymach, J. Force, I. Hoschele, C. M. Becker, J. Folkman, and O. Kisker
Therapeutic Efficacy of Endostatin Exhibits a Biphasic Dose-Response Curve
Cancer Res., December 1, 2005; 65(23): 11044 - 11050.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. J. Streck, P. V. Dickson, C. Y.C. Ng, J. Zhou, J. T. Gray, A. C. Nathwani, and A. M. Davidoff
Adeno-Associated Virus Vector-Mediated Systemic Delivery of IFN-{beta} Combined with Low-Dose Cyclophosphamide Affects Tumor Regression in Murine Neuroblastoma Models
Clin. Cancer Res., August 15, 2005; 11(16): 6020 - 6029.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. A. Prell, B. Li, J. M. Lin, M. VanRoey, and K. Jooss
Administration of IFN-{alpha} Enhances the Efficacy of a Granulocyte Macrophage Colony Stimulating Factor-Secreting Tumor Cell Vaccine
Cancer Res., March 15, 2005; 65(6): 2449 - 2456.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. P. Schneider and K. D. Miller
Angiogenesis of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1782 - 1790.
[Full Text] [PDF]

Home page
 JCOHome page
B. I. Rini and E. J. Small
Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma
J. Clin. Oncol., February 10, 2005; 23(5): 1028 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Papageorgiou, L. Lashinger, R. Millikan, H. B. Grossman, W. Benedict, C. P. N. Dinney, and D. J. McConkey
Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Interferon-Induced Apoptosis in Human Bladder Cancer Cells
Cancer Res., December 15, 2004; 64(24): 8973 - 8979.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Palamara, S. Meindl, M. Holcmann, P. Luhrs, G. Stingl, and M. Sibilia
Identification and Characterization of pDC-Like Cells in Normal Mouse Skin and Melanomas Treated with Imiquimod
J. Immunol., September 1, 2004; 173(5): 3051 - 3061.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. E. Spaner
Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells
J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Noguchi, H. Yoshiji, S. Kuriyama, J. Yoshii, Y. Ikenaka, K. Yanase, T. Namisaki, M. Kitade, M. Yamazaki, A. Mitoro, et al.
Combination of Interferon-{beta} and the Angiotensin-Converting Enzyme Inhibitor, Perindopril, Attenuates Murine Hepatocellular Carcinoma Development and Angiogenesis
Clin. Cancer Res., December 1, 2003; 9(16): 6038 - 6045.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Onn, T. Isobe, S. Itasaka, W. Wu, M. S. O'Reilly, W. Ki Hong, I. J. Fidler, and R. S. Herbst
Development of an Orthotopic Model to Study the Biology and Therapy of Primary Human Lung Cancer in Nude Mice
Clin. Cancer Res., November 15, 2003; 9(15): 5532 - 5539.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Bocci, G. Francia, S. Man, J. Lawler, and R. S. Kerbel
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
PNAS, October 28, 2003; 100(22): 12917 - 12922.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Hernberg, P. Virkkunen, P. Bono, H. Ahtinen, H. Maenpaa, and H. Joensuu
Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma
J. Clin. Oncol., October 15, 2003; 21(20): 3770 - 3776.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. N. Lara Jr., D. I. Quinn, K. Margolin, F. J. Meyers, J. Longmate, P. Frankel, P. C. Mack, C. Turrell, P. Valk, J. Rao, et al.
SU5416 Plus Interferon {alpha} in Advanced Renal Cell Carcinoma: A Phase II California Cancer Consortium Study with Biological and Imaging Correlates of Angiogenesis Inhibition
Clin. Cancer Res., October 15, 2003; 9(13): 4772 - 4781.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
O. Stoeltzing, W. Liu, N. Reinmuth, A. Parikh, S. A. Ahmad, Y. D. Jung, F. Fan, and L. M. Ellis
Angiogenesis and Antiangiogenic Therapy of Colon Cancer Liver Metastasis
Ann. Surg. Oncol., August 1, 2003; 10(7): 722 - 733.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Hao, L. A. Hammond, S. G. Eckhardt, A. Patnaik, C. H. Takimoto, G. H. Schwartz, A. D. Goetz, A. W. Tolcher, H. A. McCreery, K. Mamun, et al.
A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor
Clin. Cancer Res., July 1, 2003; 9(7): 2465 - 2471.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. C. Solorzano, R. Hwang, C. H. Baker, C. D. Bucana, P. W. Pisters, D. B. Evans, J. J. Killion, and I. J. Fidler
Administration of Optimal Biological Dose and Schedule of Interferon {alpha} Combined with Gemcitabine Induces Apoptosis in Tumor-associated Endothelial Cells and Reduces Growth of Human Pancreatic Carcinoma Implanted Orthotopically in Nude Mice
Clin. Cancer Res., May 1, 2003; 9(5): 1858 - 1867.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
Z. von Marschall, A. Scholz, T. Cramer, G. Schafer, M. Schirner, K. Oberg, B. Wiedenmann, M. Hocker, and S. Rosewicz
Effects of Interferon Alpha on Vascular Endothelial Growth Factor Gene Transcription and Tumor Angiogenesis
J Natl Cancer Inst, March 19, 2003; 95(6): 437 - 448.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. Voronov, D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C. A. Dinarello, and R. N. Apte
IL-1 is required for tumor invasiveness and angiogenesis
PNAS, March 4, 2003; 100(5): 2645 - 2650.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Koyanagi, H. Nakagawa, Y. Kuramoto, S. Ohdo, S. Soeda, and H. Shimeno
Optimizing the Dosing Schedule of TNP-470 [O-(Chloroacetyl-carbamoyl) Fumagillol] Enhances Its Antitumor and Antiangiogenic Efficacies
J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 669 - 674.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. C. Lockhart, R. D. Braun, D. Yu, J. R. Ross, M. W. Dewhirst, J. S. Humphrey, S. Thompson, K. M. Williams, B. Klitzman, F. Yuan, et al.
Reduction of Wound Angiogenesis in Patients Treated with BMS-275291, a Broad Spectrum Matrix Metalloproteinase Inhibitor
Clin. Cancer Res., February 1, 2003; 9(2): 586 - 593.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Inoue, M. Chikazawa, S. Fukata, C. Yoshikawa, and T. Shuin
Docetaxel Enhances the Therapeutic Effect of the Angiogenesis Inhibitor TNP-470 (AGM-1470) in Metastatic Human Transitional Cell Carcinoma
Clin. Cancer Res., February 1, 2003; 9(2): 886 - 899.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. D. Miller, C. J. Sweeney, and G. W. Sledge
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era
Ann. Onc., January 1, 2003; 14(1): 20 - 28.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Capillo, P. Mancuso, A. Gobbi, S. Monestiroli, G. Pruneri, C. Dell'Agnola, G. Martinelli, L. Shultz, and F. Bertolini
Continuous Infusion of Endostatin Inhibits Differentiation, Mobilization, and Clonogenic Potential of Endothelial Cell Progenitors
Clin. Cancer Res., January 1, 2003; 9(1): 377 - 382.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Bocci, K. C. Nicolaou, and R. S. Kerbel
Protracted Low-Dose Effects on Human Endothelial Cell Proliferation and Survival in Vitro Reveal a Selective Antiangiogenic Window for Various Chemotherapeutic Drugs
Cancer Res., December 1, 2002; 62(23): 6938 - 6943.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. F. Huang, S.-J. Kim, A. T. Lee, T. Karashima, C. Bucana, D. Kedar, P. Sweeney, B. Mian, D. Fan, D. Shepherd, et al.
Inhibition of Growth and Metastasis of Orthotopic Human Prostate Cancer in Athymic Mice by Combination Therapy with Pegylated Interferon-{alpha}-2b and Docetaxel
Cancer Res., October 15, 2002; 62(20): 5720 - 5726.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Sanceau, D. D. Boyd, M. Seiki, and B. Bauvois
Interferons Inhibit Tumor Necrosis Factor-alpha -mediated Matrix Metalloproteinase-9 Activation via Interferon Regulatory Factor-1 Binding Competition with NF-kappa B
J. Biol. Chem., September 13, 2002; 277(38): 35766 - 35775.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Zhang, W. Lu, and Z. Dong
Tumor-infiltrating Macrophages Are Involved in Suppressing Growth and Metastasis of Human Prostate Cancer Cells by INF-{beta} Gene Therapy in Nude Mice
Clin. Cancer Res., September 1, 2002; 8(9): 2942 - 2951.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Inoue, M. Chikazawa, S. Fukata, C. Yoshikawa, and T. Shuin
Frequent Administration of Angiogenesis Inhibitor TNP-470 (AGM-1470) at an Optimal Biological Dose Inhibits Tumor Growth and Metastasis of Metastatic Human Transitional Cell Carcinoma in the Urinary Bladder
Clin. Cancer Res., July 1, 2002; 8(7): 2389 - 2398.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Tedjarati, C. H. Baker, S. Apte, S. Huang, J. K. Wolf, J. J. Killion, and I. J. Fidler
Synergistic Therapy of Human Ovarian Carcinoma Implanted Orthotopically in Nude Mice by Optimal Biological Dose of Pegylated Interferon {alpha} Combined with Paclitaxel
Clin. Cancer Res., July 1, 2002; 8(7): 2413 - 2422.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. L. Brassard, M. J. Grace, and R. W. Bordens
Interferon-{alpha} as an immunotherapeutic protein
J. Leukoc. Biol., April 1, 2002; 71(4): 565 - 581.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. I. Izawa, P. Sweeney, P. Perrotte, D. Kedar, Z. Dong, J. W. Slaton, T. Karashima, K. Inoue, W. F. Benedict, and C. P. N. Dinney
Inhibition of Tumorigenicity and Metastasis of Human Bladder Cancer Growing in Athymic Mice by Interferon-{beta} Gene Therapy Results Partially from Various Antiangiogenic Effects Including Endothelial Cell Apoptosis
Clin. Cancer Res., April 1, 2002; 8(4): 1258 - 1270.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. O. Siefker-Radtke, R. E. Millikan, S.-M. Tu, D. F. Moore Jr, T. L. Smith, D. Williams, and C. J. Logothetis
Phase III Trial of Fluorouracil, Interferon Alfa-2b, and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Metastatic or Unresectable Urothelial Cancer
J. Clin. Oncol., March 1, 2002; 20(5): 1361 - 1367.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
I. HARTLAPP, R. ABE, R. W. SAEED, T. PENG, W. VOELTER, R. BUCALA, and C. N. METZ
Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo
FASEB J, October 1, 2001; 15(12): 2215 - 2224.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. Slaton, T. Karashima, P. Perrotte, K. Inoue, S. J. Kim, J. Izawa, D. Kedar, D. J. McConkey, R. Millikan, P. Sweeney, et al.
Treatment with Low-Dose Interferon-{alpha} Restores the Balance between Matrix Metalloproteinase-9 and E-Cadherin Expression in Human Transitional Cell Carcinoma of the Bladder
Clin. Cancer Res., September 1, 2001; 7(9): 2840 - 2853.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Muhr, O. Gudjonsson, A. Lilja, M. Hartman, Z.-J. Zhang, and B. Langstrom
Meningioma Treated with Interferon-{alpha}, Evaluated with [11C]-L-Methionine Positron Emission Tomography
Clin. Cancer Res., August 1, 2001; 7(8): 2269 - 2276.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
J. I. Izawa and C. P.N. Dinney
The role of angiogenesis in prostate and other urologic cancers: a review
Can. Med. Assoc. J., March 1, 2001; 164(5): 662 - 670.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. D. Miller, C. J. Sweeney, and G. W. Sledge Jr
Redefining the Target: Chemotherapeutics as Antiangiogenics
J. Clin. Oncol., February 15, 2001; 19(4): 1195 - 1206.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. L. Korn, S. G. Arbuck, J. M. Pluda, R. Simon, R. S. Kaplan, and M. C. Christian
Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?
J. Clin. Oncol., January 1, 2001; 19(1): 265 - 272.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Kuniyasu, W. Yasui, H. Shinohara, S. Yano, L. M. Ellis, M. R. Wilson, C. D. Bucana, T. Rikita, E. Tahara, and I. J. Fidler
Induction of Angiogenesis by Hyperplastic Colonic Mucosa Adjacent to Colon Cancer
Am. J. Pathol., November 1, 2000; 157(5): 1523 - 1535.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Inoue, J. W. Slaton, D. W. Davis, D. J. Hicklin, D. J. McConkey, T. Karashima, R. Radinsky, and C. P. N. Dinney
Treatment of Human Metastatic Transitional Cell Carcinoma of the Bladder in a Murine Model with the Anti-Vascular Endothelial Growth Factor Receptor Monoclonal Antibody DC101 and Paclitaxel
Clin. Cancer Res., July 1, 2000; 6(7): 2635 - 2643.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.